Value of ablation therapy in the treatment of lung metastases

Qi, Han; Fan, Weijun

doi:10.1111/1759-7714.12567

Cited by 23 publications

(29 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Previous studies investigating treatment outcomes in patients with pulmonary metastases were retrospective reviews of patients treated with a single modality for primary cancers of diverse origins. [19][20][21] Surgery is initially recommended for the local treatment of pulmonary metastases. 14,22 The indications for treatment via metastasectomy have been relatively well studied compared to SBRT, and include good PS, long disease-free survival, and the absence of synchronous metastases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases

et al. 2018

View full text Add to dashboard Cite

BackgroundWe compared the treatment outcomes of stereotactic body radiotherapy (SBRT) and metastasectomy in patients with pulmonary metastases.MethodsTwenty‐one patients received SBRT (total radiation doses 60 Gy in 3 fractions or 48 Gy in 4 fractions) and 30 underwent metastasectomy, most (93.3%) with wedge resection. The patients were followed for a median of 13.7 months. The tumor size in the SBRT group was larger than in the metastasectomy group (median 2.5 vs. 1.25 cm; P = 0.015). Patients with synchronous metastases were more likely to be treated with SBRT than with metastasectomy (P = 0.006).ResultsThere was no significant difference in the local control rates of the treatment groups (P = 0.163). Progression‐free survival (PFS) was longer in the metastasectomy than in the SBRT group (P = 0.02), with one and two‐year PFS rates of 51.1% and 46% versus 23.8% and 11.9%, respectively. The one and two‐year overall survival (OS) rates were 95% and 81.8% in the metastasectomy group and 79.5% and 68.2%, in the SBRT group, respectively. In multivariate analysis, synchronous metastasis was related to poor PFS, and tumor size was the most significant factor affecting OS. There were no significant differences in PFS and OS between treatment groups after dividing patients according to the presence or absence of synchronous metastases.ConclusionsSBRT is considered a suitable local modality against pulmonary metastases; however, patients with synchronous metastases are only likely to obtain a small benefit from local treatment with either SBRT or surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…RFA of lung metastases offers a minimally invasive, repeatable treatment, with better preservation of lung function treatment when compared to surgical resection [ 8 ]. No studies directly compare RFA with surgery, but published results suggest local control and survival rates similar to surgery [ 8 , 9 ]. Long-term survival data on RFA remain limited when compared to the surgical literature, making it difficult to draw definitive conclusions on the long-term oncological durability of the treatment [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Outcomes in Percutaneous Radiofrequency Ablation for Histologically Proven Colorectal Lung Metastasis

Zhong

Palkhi

et al. 2020

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Introduction To evaluate the long-term outcome of image-guided radiofrequency ablation (RFA) when treating histologically confirmed colorectal lung metastasis in terms of overall survival (OS), progression-free survival (PFS) and local tumour control (LTC). Materials and Methods Retrospective single-centre study. Consecutive RFA treatments of histologically proven lung colorectal metastases between 01/01/2008 and 31/12/14. The primary outcome was patient survival (OS and PFS). Secondary outcomes were local tumour progression (LTP) and complications. Prognostic factors associated with OS/ PFS were determined by univariate and multivariate analyses. Results Sixty patients (39 males: 21 females; median age 69 years) and 125 colorectal lung metastases were treated. Eighty percent (n = 48) also underwent lung surgery for lung metastases. Mean metastasis size (cm) was 1.4 ± 0.6 (range 0.3–4.0). Median number of RFA sessions was 1 (1–4). During follow-up (median 45.5 months), 45 patients died (75%). The estimated OS and PFS survival rates at 1, 3, 5, 7, 9 years were 96.7%, 74.7%, 44.1%, 27.5%, 16.3% (median OS, 52 months) and 66.7%, 31.2%, 25.9%, 21.2% and 5.9% (median PFS, 19 months). The LTC rate was 90% with 6 patients developing LTP with 1-, 2-, 3- and 4-year LTP rates of 3.3%, 8.3%, 10.0% and 10.0%. Progression-free interval < 1 year (P = 0.002, HR = 0.375) and total number of pulmonary metastases (≥ 3) treated (P = 0.037, HR = 0.480) were independent negative prognostic factors. Thirty-day mortality rate was 0% with no intra-procedural deaths. Conclusion The long-term OS and PFS following RFA for the treatment of histologically confirmed colorectal lung metastases demonstrate comparable oncological durability to surgery.

show abstract

“…In addition, lung cancers are heterogeneous with genomic and phenotypic differences not only among different patients but also within the same patient 5 . Therefore, treatments that are independent of driver mutations have broader applications when used as a monotherapy for primary lung cancer or in combination for treatment of metastases to the lung from cancers in other organs 6 , 7 .…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers

Ahn

Carrington

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Treatment of cancers in the lung remains a critical challenge in the clinic for which gene therapy could offer valuable options. We describe an effective approach through systemic injection of engineered polymer/DNA nanoparticles that mediate tumor-specific expression of a therapeutic gene, under the control of the cancer-selective progression elevated gene 3 (PEG-3) promoter, to treat tumors in the lungs of diseased mice. A clinically tested, untargeted, polyethylenimine carrier was selected to aid rapid transition to clinical studies, and a CpG-free plasmid backbone and coding sequences were used to reduce inflammation. Intravenous administration of nanoparticles expressing murine single-chain interleukin 12, under the control of PEG-3 promoter, significantly improved the survival of mice in both an orthotopic and a metastatic model of lung cancer with no marked symptoms of systemic toxicity. These outcomes achieved using clinically relevant nanoparticle components raises the promise of translation to human therapy.

show abstract

Value of ablation therapy in the treatment of lung metastases

Cited by 23 publications

References 71 publications

Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases

Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases

Long-Term Outcomes in Percutaneous Radiofrequency Ablation for Histologically Proven Colorectal Lung Metastasis

Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers

Contact Info

Product

Resources

About